Cost effectiveness of quality control in bacteriology. 1982

R C Bartlett, and C A Rutz, and N Konopacki

The cost effectiveness of quality control in bacteriology stipulated by regulators is not established. The authors evaluated 111 surveillance procedures applied to 54 different operations; 100 had been performed in the authors' lab between 1965 and 1980, 91 of which had been performed 50 times. Forty-six conformed to CLIA requirements (CLIA-P). Thirty-seven others were CLIA-P, which had been modified (CLIA-PM) by reducing frequency and extent because few or no deficiencies had been observed. Eight others were devised by the authors (HH-P). The number detecting deficiencies, the per cent, and the mean per cent of deficiencies detected were: CLIA-P, 31, 67%, 3.5%; CLIA-PM, 8, 22%, 2.1%; HH-P, 8, 100%, 8.8%. Compliance with CLIA would cost HH $20,700/year (3.4% of total bacteriology laboratory cost). HH-P would cost an additional $9000/year. Discontinuation of CLIA-P not detecting deficiencies would reduce HH costs by $2900/year. Application of other low yield CLIA-P only to new lots of selected dehydrated media and fresh batches of selected reagents would reduce cost further by $2000/year.

UI MeSH Term Description Entries
D007753 Laboratories Facilities equipped to carry out investigative procedures. Laboratory
D011786 Quality Control A system for verifying and maintaining a desired level of quality in a product or process by careful planning, use of proper equipment, continued inspection, and corrective action as required. (Random House Unabridged Dictionary, 2d ed) Control, Quality,Controls, Quality,Quality Controls
D003237 Connecticut State bounded on the north by Massachusetts, on the east by Rhode Island, on the south by Long Island Sound, and on the west by New York.
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D006773 Hospitals, Municipal Hospitals controlled by the city government. Hospitals, City, Public-Owned,Hospitals, City, Public Owned,Municipal Hospitals,Hospital, Municipal,Municipal Hospital
D001432 Bacteriology The study of the structure, growth, function, genetics, and reproduction of bacteria, and BACTERIAL INFECTIONS.

Related Publications

R C Bartlett, and C A Rutz, and N Konopacki
September 1969, The American journal of medical technology,
R C Bartlett, and C A Rutz, and N Konopacki
July 1981, Journal of clinical microbiology,
R C Bartlett, and C A Rutz, and N Konopacki
May 1968, Proceedings of the Royal Society of Medicine,
R C Bartlett, and C A Rutz, and N Konopacki
December 1971, Journal of clinical pathology,
R C Bartlett, and C A Rutz, and N Konopacki
January 1995, Klinicheskaia laboratornaia diagnostika,
R C Bartlett, and C A Rutz, and N Konopacki
January 1967, The American journal of medical technology,
R C Bartlett, and C A Rutz, and N Konopacki
November 1992, Schweizerische medizinische Wochenschrift,
R C Bartlett, and C A Rutz, and N Konopacki
January 1971, The American journal of medical technology,
R C Bartlett, and C A Rutz, and N Konopacki
March 1973, Journal of the Air Pollution Control Association,
R C Bartlett, and C A Rutz, and N Konopacki
February 2000, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!